Stockreport

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain ...

Sonnet BioTherapeutics Holdings, Inc.  (SONN) 
PDF binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) IL-18 BPR was linked to Sonnet's proprieta [Read more]